Persistent pulmonary hypertension in newborn (PPHN) is a serious and possibly fatal
syndrome characterized by sustained foetal elevation of pulmonary vascular resistance at …

Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of
BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine …

Pulmonary arterial hypertension (PAH) is a rare but life‐threatening disease that progresses
rapidly and is currently without a cure. Pharmacological treatments aim to slow down …

Background Pembrolizumab is an immune check-point inhibitor (ICI), which acts by blocking
the T lymphocyte PD-1 inhibitor receptor. It has been increasingly used in advanced or non …

Background Selexipag is an oral selective prostacyclin IP receptor agonist approved in
patients with low-and intermediate-risk pulmonary hypertension (PH); evidence in patients at …

Hipertensión arterial pulmonar: selexipag Agonista selectivo del receptor de prostaciclina vía
oral Page 1 INSUFICIENCIA CARDIACA Insuf Card 2019;14(1):34-44 34 LL Lobo Márquez y …

Pulmonary hypertension is a condition in which the blood pressure in the arteries of the
lungs and the right side of the heart becomes elevated. This may be due to blockage …

Increasing Awareness about Pulmonary Arterial Hypertension Treatment for Nurses - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

La hipertensión arterial pulmonar (HAP) es una enfermedad rara, pero cuando no se trata
no sólo disminuye la calidad de vida del paciente, sino que pone en peligro su vida. La HAP …

Pulmonary artery hypertension (PAH) is still an important cause of morbidity and mortality in
children. Despite recent developments in PH-specific therapies, survival of patients with …